Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 88 publications.

Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403

Shamarina D, Sluga-O'Callaghan M, Kassianos G, Marijam A, Dave V, Davenport E, Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults. Vaccines (Basel). 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645

Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, Curran D, Deeywadaa P, Marijam A, Andani A. Knowledge and attitudes of European HCPs towards hepatitis A and B vaccination of adults at risk. Poster presented at the Global Hepatitis Summit 2023; April 25, 2023. Paris, France. Previously presented at the 15th European Public Health Conference 2022 (EPH).

Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3

Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4

Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194

Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Buck PM. Hepatitis A and Hepatitis B vaccination in adult patients at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Herrera-Restrepo O, Davis K, Sweeney C, Davenport E, Ghaswalla P, Buck PO. Hepatitis A and B vaccination in adults at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, Curran D, Marijam A, Andani A. Knowledge and attitudes of European HCPs towards hepatitis A and B vaccination of adults at risk. Poster presented at the 15th European Public Health Conference 2022 (EPH); November 9, 2022. Berlin, Germany.

Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Herrera-Restrepo O, Buck PO. Health care providers' knowledge, practices, and barriers to hepatitis vaccination guidelines. J Nurse Pract. 2022 Feb 16;18:403-10.

DiBenedetti D, Mansfield C, Myers K, Satram S, Reyes C. Understanding patient experiences with chronic Hepatitis B Virus (cHBV) and its treatments. Poster presented at the AASLD 2021 The Liver Meeting; November 12, 2021. Previously presented at the Virtual ISPOR 2021 Conference.

Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Andani A, Buck PO. What can Europe learn from HCP knowledge and attitudes towards hepatitis A vaccination in the US? Poster presented at the 14th European Public Health Virtual Conference 2021 (EPH); November 10, 2021.

Danysh HE, Gilsenan A, Arana A, Pladevall-Vila M, Layton JB, Ziemiecki R, Chen H, Hunt PR, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in the clinical practice research datalink. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Layton JB, Ziemiecki R, Danysh HE, Gaber C, Gilsenan A, Johannes CB. Graphical representation of an array of quantitative bias analysis scenarios for differential outcome misclassification. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Layton JB, Ziemiecki R, Danysh H, Gilsenan A, Johannes C. Graphical representation of multiple quantitative bias analysis scenarios for unmeasured confounding. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Johannes C, Layton JB, Beachler DM, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of acute kidney injury in real-world use of dapagliflozin. Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.

Johannes C, Layton JB, Beachler DC, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of severe complications of urinary tract infection in real-world use of dapagliflozin. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.

Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Herrera-Restrepo O, Buck P. Knowledge, attitudes, practices and barriers regarding Hepatitis A and Hepatitis B vaccination: a survey of healthcare providers. Poster presented at the American Association of Nurse Practitioners (AANP) National Conference; June 15, 2021.

Layton JB, Zhou CK, Danysh HE, Bleachler DC, Ziemiecki R, Dinah J, Yin R, Calingaert B, Hunt PR, Gilsenan AW, Johannes CW. Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia de Albeniz X, Hunt PR, Gilsenan A, Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772

Danysh HE, Layton B, Beachler DC, Arana A, Pladevall-Vila M, Schmid R, Calingaert B, Ziemiecki R, Hunt PR, Gilsenan A, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.

Herring WL, Gould IG, Wittrup-Jensen V, Kuti E, Mettam S, Ertle J, Wolowacz S. A conceptual model for the economic evaluation of emerging nonalcoholic steatohepatitis therapies: the impact of treatment efficacy profiles on health outcomes. Poster presented at the 2020 SMDM 18th Biennial European Conference (Conference cancelled); June 16, 2020.

Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.

Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822

Timmer A, de Sordi D, Kappen S, Kohse KP, Schink T, Perez-Gutthann S, Jacquot E, Deltour N, Pladevall M. Validity of hospital ICD-10-GM codes to identify acute liver injury in Germany. Pharmacoepidemiol Drug Saf. 2019 Oct;28(10):1344-52. doi: 10.1002/pds.4855

Forns J, Pottegard A, Reinders T, Poblador-Plou B, Morros R, Brandt L, Cainzos-Achirica M, Hellfritzsch M, Schink T, Prados-Torres A, Giner-Soriano M, Hallas J, Cortes J, Hagg D, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M, Reutfors J. Antidepressant use in Denmark, Germany, Spain, and Sweden from 2009 to 2014: incidence and comorbidities of antidepressant initiators. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):560. doi: 10.1002/pds.4864

Forns J, Pottegard A, Reinders T, Poblador-Plou B, Morros R, Brandt L, Cainzos-Achirica M, Hellfritzsch M, Schink T, Prados-Torres A, Giner-Soriano M, Hagg D, Hallas J, Cortes J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M, Reutfors J. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019 Apr 15;249:242-52. doi: 10.1016/j.jad.2019.02.010

Pladevall M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries. Poster presented at the 31st ECNP Congress; October 8, 2018. Barcelona, Spain. Previously presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: a vaccine safety datalink study. Vaccine. 2018 Oct 1;36(41):6111-6. doi: 10.1016/j.vaccine.2018.08.074

Pladevall M, Hallas J, Schink T, Reutfors J, Morros R, Poblador-Plou B, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Pottegard A, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a PASS in four European countries. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. doi: 10.1002/pds.4629

Forns J, Cainzos-Achirica M, Hellfritzsch M, Giner-Soriano M, Poblador-Plou B, Hallas J, Morros R, Prados-Torres A, Pottegard A, Cortes J, Aguado J, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M. How valid are the codes used to identify acute liver injury (ALI)? A study in 3 European data sources. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug 17; 27(S2):371-2. doi: 10.1002/pds.4629

Timmer A, Kappen S, de Sordi D, Pladevall M, Perez-Gutthann S, Jacquot E, Deltour N, Schink T. Validity of hospital ICD-10-GM codes to identify acute liver injury. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):262. doi: 10.1002/pds.4629

Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9

Hoogeveen EK, Rothman KJ, Voskamp PWM, de Mutsert R, Halbesma N, Dekker FW. Obesity and risk of death or dialysis in younger and older patients on specialized pre-dialysis care. PLoS One. 2017 Sep 5;12(9):e0184007. doi: 10.1371/journal.pone.0184007

Pladevall M, Hallas J, Schink T, Morros R, Poblador-Plou B, Forns J, Hellfritzsch M, Reinders T, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Pottegard A, Kollhorst B, Cortes J, Aguado J, Perlemuter G, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and risk of hospitalization for acute liver injury: nested case-control study in Spain, Germany, and Denmark. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):389. doi: 10.1002/pds

Johannes C, Beachler D, Ziemiecki R, Yin R, McGrath L, Jemison J, Lanes S, Gilsenan A. Characteristics of new users of dapagliflozin and other antidiabetic drugs: United States and United Kingdom. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):129. doi: 10.1002/pds

Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017 Jul;36(7):e189-96. doi: 10.1097/INF.0000000000001548

Mauskopf JA, Mitchell SE, Samuel M, Samp JC. Systematic literature review to identify cost estimates of liver disease in those with chronic hepatitis c virus (HCV) in the United States. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Mauskopf JA, Mitchell SE, Samuel M. Estimating costs in a cost-effectiveness analysis: adherence to HTA guidance. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.

Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295

Sommer WH, Ceelen F, Garcia-Albeniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013 Nov;23(11):3094-103. doi: 10.1007/s00330-013-2925-8

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.

Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.

Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A decision-analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the American Association for the Study of Liver Diseases; November 1, 2013.

Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Cure S. Evaluation of long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the Annual Meeting of the American Association for the Study of Liver Diseases; November 1, 2013.

Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.

Kaye JA, Castellsague J, Bui C, Calingaert B, McQuay LJ, Riera N, Saltus C, Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S. Risk of acute liver injury in a cohort of oral antimicrobial users. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(Supp 3):92. doi: 10.1002/phar.1367

Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.